ARS Pharmaceuticals (SPRY) Amortizatization of Intangibles (2020 - 2026)

ARS Pharmaceuticals has reported Amortizatization of Intangibles for 5 years, with the latest figure at $990000.0 in Q1 2026.

• Quarterly Amortizatization of Intangibles fell 49.52% year-over-year to $990000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 59.34% YoY) and the FY2025 annual result came in at $5.5 million, down 23.86% from the prior year.
• Amortizatization of Intangibles slipped to $990000.0 in Q1 2026 per SPRY's latest filing, from $1.0 million in the prior quarter.
• Over five years, Amortizatization of Intangibles peaked at $5.9 million in Q2 2024 and troughed at -$2.0 million in Q1 2024.
• A 5-year average of $514571.4 and a median of $996500.0 in 2025 frame the typical range for Amortizatization of Intangibles.
• The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles sank 705.96% in 2023, then soared 434.7% in 2024.
• Over 5 years, Amortizatization of Intangibles stood at $285000.0 in 2022, then sank by 705.96% to -$1.7 million in 2023, then soared by 189.4% to $1.5 million in 2024, then slumped by 35.04% to $1.0 million in 2025, then fell by 1.3% to $990000.0 in 2026.
• According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $990000.0, $1.0 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.